Pyramid 2 + Type II BVD (Canada)This page contains information on Pyramid 2 + Type II BVD for veterinary use.
The information provided typically includes the following:
- Pyramid 2 + Type II BVD Indications
- Warnings and cautions for Pyramid 2 + Type II BVD
- Direction and dosage information for Pyramid 2 + Type II BVD
Pyramid 2 + Type II BVDThis treatment applies to the following species:
Bovine Rhinotracheitis - Virus Diarrhea Vaccine
Modified Live Virus
Veterinary use only
Pyramid 2 + Type II BVD Indications
For vaccination of healthy cattle as an aid in the prevention of disease caused by bovine rhinotracheitis virus and bovine virus diarrhea (types 1 and 2). This product aids in the prevention of persistent BVD type 1 and type 2 infection of the fetal calf when it is used subcutaneously in the cow or heifer 30 to 60 days pre-breeding. This vaccine may be used in pregnant cows or calves nursing pregnant cows provided the cows were vaccinated pre-breeding, according to label instructions, with any Express® FP vaccine, Pyramid FP 5, Pyramid FP 10, Pyramid 2 + Type II BVD or Pyramid FP 5 + Presponse SQ.
This product contains IBR and BVD types 1 and 2 modified live viruses. Contains neomycin, polymyxin B, and thimerosal as preservatives.
Pyramid 2 + Type II BVD Dosage And Administration
Aseptically rehydrate with the accompanying diluent. Shake well. Inject one 2 mL dose subcutaneously, using aseptic technique. Annual revaccination is recommended. Protect animals from exposure for at least 14 days after vaccination. Calves vaccinated under 6 months of age should be revaccinated at 6 months of age.
Summary Of Pregnant Cow Safety Study
Safety in pregnant cows and heifers was demonstrated in trials conducted in three separate herds of more than 1,400 cows. Prior to breeding, all animals were vaccinated with Pyramid FP 5, a modified live virus (MLV) vaccine containing IBR, BVD types 1 & 2, PI3, and BRSV. During the first, second or third trimester of pregnancy, the animals were vaccinated again. The pregnant cows received either Pyramid FP 5 or a killed virus (KV) IBR, BVD types 1 & 2, PI3, and BRSV vaccine (Triangle® 4 + Type II BVD). From pregnancy vaccination through calving, the cows were observed for fetal loss. Fetal loss in both groups was similar with 0.9% in the Pyramid FP 5 vaccinated groups and 1.6% in the KV vaccinated groups. In addition, no abortions due to IBR or BVD were identified in either group. Following birth, each calf’s health was monitored for 30 days. The health of calves born to Pyramid FP 5 vaccinated dams was similar to the health of calves born to the KV vaccinated dams. Fetal health risks associated with vaccination of pregnant animals with modified live vaccines cannot be unequivocally determined by clinical trials conducted for licensure. Vaccination of pregnant animals with modified live vaccines should be discussed with a veterinarian.
Store in dark at 2-7°C. Do not freeze. Use entire contents when first opened. A small percentage of animals may show transient mild injection site swelling. Do not vaccinate within 21 days before slaughter. Burn container and all unused contents. In case of anaphylactoid reaction, administer epinephrine.
Pyramid® and Triangle® are registered trademarks of Boehringer Ingelheim Vetmedica, Inc. Express® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH. Used under license.
Manufactured by: Boehringer Ingelheim Vetmedica, Inc., St. Joseph, Missouri 64506 U.S.A.
US Vet. Lic. No. 124
Manufactured for: Boehringer Ingelheim (Canada) Ltd., Burlington, Ontario L7L 5H4
50 Doses, Rehydrate to 100 mL
NAC No.: 1230104.2
5180 SOUTH SERVICE ROAD, BURLINGTON, ON, L7L 5H4
|Customer Care No.:||1-800-567-1885|
|Technical Services No.:||1-877-565-5501|
|Every effort has been made to ensure the accuracy of the Pyramid 2 + Type II BVD information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.|
Copyright © 2018 Animalytix LLC. Updated: 2018-10-31